A study of more than two million people with diabetes builds on evidence of broad-ranging benefits and risks of glucagon-like peptide 1 receptor ... assessing GLP-1 RA treatment in comparison ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback